Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Thursday, December 21, 2017
Impax Laboratories has entered into a definitive agreement to sell its manufacturing facility in Taiwan to Bora Pharmaceuticals.
read more
Impax Laboratories, Inc. announced that its Board of Directors has appointed Paul M. Bisaro as Impax's President and Chief Executive Officer and a member of the Company's Board, effective March 27, 2017. Mr. Bisaro will succeed J. Kevin Buchi, who ...
read more
Thursday, September 17, 2015
Impax Laboratories has announced that the FDA has approved generic Mestinon Timespan Tablets (pyridostigmine bromide extended release), 180 mg.
read more
Wednesday, February 08, 2017
Impel NeuroPharma, a Seattle-based clinical stage biotechnology company developing first-in-class intranasal drug treatments announced has entered into service agreements with Camargo Pharmaceutical Services, LLC ("Camargo").
read more
Wednesday, November 12, 2014
Implandata Ophthalmic Products GmbH (Implandata) an ophthalmic surgical product and e-Health start-up company announces the closing of a €3M Series B-Round. Born2Grow Venture Partners, a private fund based in Heilbronn/Germany joins in as new ...
read more
Wednesday, January 24, 2018
Imprimis announced its New Jersey FDA-registered outsourcing facility has been issued a DEA Manufacturer Controlled Substance Registration Certificate.
read more
Friday, February 17, 2017
Imprimis Pharmaceuticals has begun shipping its core sterile ophthalmic medications to select customers from its FDA-registered outsourcing facility without the need for a patient-specific prescription. Over the next few weeks Imprimis' flagship ...
read more
Imprimis Pharmaceuticals has filed for registration of its recently-constructed New Jersey facility with the U.S. Food and Drug Administration (FDA) as a 503B outsourcing facility. The state-of-the-art facility is expected to begin manufacturing as ...
read more
Imprimis Pharmaceuticals, a pharmaceutical company focused on the development and commercialization of proprietary and customizable drug formulations, announced that it has filed for registration of its ImprimisRx TX pharmacy, located in Allen, Texas...
read more
Imprimis Pharmaceuticals has made available a customizable compounded formulation of pyrimethamine and leucovorin available for physicians to consider prescribing for their patients as a low cost alternative to Daraprim®.
read more
Imprimis Pharmaceuticals has announced that it has commenced construction on the company's Allen, Texas compounding pharmacy and plans to register the pharmacy with the U.S. Food and Drug Administration (FDA) as a 503B sterile outsourcing facility ...
read more
ImprimisRx has agreed to a product supply agreement with Vision Center Network of America (VCNA).
read more
Tuesday, December 10, 2019
ImprimisRx announced that on December 9, 2019, its FDA-registered 503B outsourcing facility received a non-resident operating license and has now begun shipping into California.
read more
ImprimisRx has agreed to a product supply agreement with iOR Partners.
read more
ImprimisRx has agreed to a product supply agreement with EyeCare Services Partners (ESP).
read more